Oncology-focused biotech company Blaze Bioscience today released clinical data from the Phase 1 study of its Tumor Paint BLZ-100 in pediatric brain cancer patients, touting that the agent was well tolerated. Data from the study was presented at the 4th Biennial Pediatric Neuro-Oncology Basic and Translational Research Conference in New York. The BLZ-100 is the […]
Featured
BD recalls select Plastipak catheter tip syringes over leakage issues
Becton Dickinson (NYSE: BDX) is initiating a voluntary product recall for its 100ml Plastipak catheter tip syringes over leakage issues the company caught during testing. The Franklin Lakes, N.J. company discovered that the devices, which are labeled with a 5-year expiration date, were found to be failing during routine real-time stability tests, beginning at the […]
Sanofi, Parexel collaborate on clinical trial data collection wearables
Parexel said today it is collaborating with Sanofi (NYSE:SNY) to develop and promote wearable devices to improve collection of data during clinical trials. Through the collaborative deal, the 2 companies will leverage their specific expertise to explore how wearables could improve study performance and new drug development and how sensors from several wearable devices could be […]
Lilly wins FDA nod for Humalog pre-filled Junior KwikPen device
Eli Lilly (NYSE:LLY) said today that the FDA approved its Humalog Junior KwikPen for the treatment of diabetes. The device is a pre-filled pen with half-unit dosing capabilities, which Eli Lilly said gives patients access to finer dose adjustment. “We are pleased to be able to meet the needs of people who prefer a prefilled […]
Mallinckrodt responds to probe into pricey injection pain-killer
Mallinckrodt Pharmaceuticals (NYSE:MNK) issued a response today to Sen. Claire McCaskill (D-Mo.) and her probe into the company’s pricing strategies for its injectable pain-killer, Ofirmev. McCaskill wrote to the company at the end of May, suggesting that that the company’s price increases could have cost hospitals millions and may have pushed healthcare practitioners to use cheaper painkillers, including highly […]
Study: PharmaJet’s needle-free injection tech linked to higher workplace flu shot compliance
PharmaJet touted its needle-free injection technology in a study that evaluated the use of its device in company-hosted flu clinics. The report, which was published in ONdrugDelivery, described the experience that patients and healthcare providers had with its Stratis needle-free injection system in influenza clinics hosted by companies including BP Oil, Cargill, Xerox and the Denver International […]
BoneSupport readies $62m IPO
BoneSupport said this week that it’s planning to float an initial public offering that would fetch roughly $62 million at the midpoint, not including an over-allotment option. The Swedish company, which is developing the Cerament G injectable antibiotic-eluting bone graft substitute, said it plans to offer more than 18.5 million shares at $3.13 to $3.59 apiece […]
Braeburn names former Teva exec as new president, CEO | Personnel Moves – June 14, 2017
Braeburn Pharmaceuticals said last week that it named Michael Derkacz as president and CEO of the buprenorphine implant-maker. Most recently, Derkacz worked as senior VP and head of global central nervous system and pain therapeutic areas for Teva Pharmaceuticals (NYSE:TEVA). Behshad Sheldon, who helped to found Braeburn in 2012, is slated to step down from Braeburn […]
pSivida implant meets primary endpoint in late-stage trial
pSivida (NSDQ:PSDV) touted data from the 2nd Phase III trial of its Durasert 3-year treatment for posterior segment uveitis. The company reported that the trial, which followed patients for 3 years, met its primary endpoint of prevention of recurrence of posterior uveitis at 6 months. In the 153-patient trial, 21.8% of Durasert-treated patients had a […]
Delpor wins $1.5m NIH grant for diabetes drug implant
Delpor Inc. said today that it won a $1.5 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases to support the development of its exenatide implant. The implant was designed for patients with Type II diabetes and features Delpor’s Nanopor technology, which uses passive diffusion to deliver therapeutic levels of exenatide […]